Drug Development

Cynthia A. Challener is a contributing editor to Pharmaceutical Technology.

Articles

Without an independent approval pathway for novel excipients, true pharmaceutical innovation could be stymied.

Novel Excipients Needed More Than Ever Before

Felicity Thomas is the former Associate Editorial Director of Pharmaceutical Technology, Pharmaceutical Technology Europe, BioPharm International.

Various strategies to improve bioavailability are being continuously evaluated, affording greater commercial prospects for the future.

Reviewing Recent Bioavailability Research

FDA moves recommended timeline for API and drug manufacturers to assess impurity risks to March 31, 2021.

Nitrosamine Risk Assessment Date Extended

The company will join the network of approved manufacturers of the lipid excipients. 

AMRI to Develop and Manufacture Lipid Excipients for Pfizer-BioNTech COVID-19 Vaccine

The deal expands Wavelength’s drug substance manufacturing footprint and its API CDMO business.

Wavelength Pharmaceuticals Acquires Vanamali Organics

The increased services will work in conjunction with the site’s SimpliFiH Solutions first-in-human services, which includes phase-appropriate drug substance and drug product development and manufacturing.

Lonza to Expand its Small Molecule Services at Oregon Site

Nanoform and Herantis have signed a biologics proof of concept agreement for formulation proof of concept projects aimed at improving nasal drug delivery to the brain.

Nanoform, Herantis Collaborate on Nasal Drug Delivery to the Brain of Biologics

Videos

The importance of characterizing excipients, supply chain security, and the role of novel excipients are explored.

Excipient Quality and Impact on Formulation

The CGMP manufacturing agreement will expand production of lenzilumab, a candidate for COVID-19 therapy, to support a potential emergency use authorization filing.

Avid Bioservices Enters Manufacturing Agreement with Humanigen for Lenzilumab

Plasma-based proteins and cell-based therapies have significant potential to address unmet medical needs.

APIs and Excipients